"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA GRANTED ACCELERATED APPROVAL TO PEMBROLIZUMAB (KEYTRUDA) FOR ADULT AND PEDIATRIC PATIENTS WITH MSI-H OR DMMR SOLID TUMORS THAT HAVE PROGRESSED FOLLOWING PRIOR TREATMENT

FDA GRANTED ACCELERATED APPROVAL TO PEMBROLIZUMAB (KEYTRUDA) FOR ADULT AND PEDIATRIC PATIENTS WITH MSI-H OR DMMR SOLID TUMORS THAT HAVE PROGRESSED FOLLOWING PRIOR TREATMENT

25 May 2017 11:20 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with unresectable or metastatic, miicrosatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or with MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software